Evidence map›Paper›PMID 34244013›Full record

ArticleJournal of substance abuse treatment2021

Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting.

Steffani R Bailey, Jennifer A Lucas, Heather Angier, Rebecca E Cantone, Joan Fleishman, Brian Garvey, Deborah J Cohen, Rebecca E Rdesinski, Leah Gordon

Abstract read
In one paragraph

Article in Journal of substance abuse treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Organization of primary care and early MOUD discontinuation.Addiction science & clinical practice · 2024
    Article
  8. Article
  9. Article
  10. Observational
  11. Observational
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Steffani R BaileyDepartment of Family Medicine, Oregon Health & Science University (OHSU), United States of America. Electronic address: bailstef@ohsu.edu.
Jennifer A LucasDepartment of Family Medicine, Oregon Health & Science University (OHSU), United States of America.
Heather AngierDepartment of Family Medicine, Oregon Health & Science University (OHSU), United States of America.
Rebecca E CantoneDepartment of Family Medicine, Oregon Health & Science University (OHSU), United States of America.
Joan FleishmanDepartment of Family Medicine, Oregon Health & Science University (OHSU), United States of America.
Brian GarveyDepartment of Family Medicine, Oregon Health & Science University (OHSU), United States of America.
Deborah J CohenDepartment of Family Medicine, Oregon Health & Science University (OHSU), United States of America.
Rebecca E RdesinskiDepartment of Family Medicine, Oregon Health & Science University (OHSU), United States of America.
Leah GordonDepartment of Family Medicine, Oregon Health & Science University (OHSU), United States of America.

Funding

Meaningful Use and Treatment of Smoking in Federally-Qualified Health CentersK23DA037453 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI BAILEY, STEFFANI R · 2015 to 2019
$841k
NIDA NIH HHS K23 DA037453
6 · The paper itself

Abstract

introductionBuprenorphine, a medication for opioid use disorder (OUD), can be administered within primary care; however, little is known about characteristics associated with retention on buprenorphine in these settings. This study examines patient correlates of buprenorphine retention and whether an integrated, interdisciplinary treatment model (buprenorphine and behavioral health) is associated with higher odds of buprenorphine retention than a primarily medication-only treatment model.

methodsElectronic health record data from adult patients with an OUD, ≥1 buprenorphine order and ≥1 visit to either of two primary care clinics between 9/2/2014-6/27/2018 were extracted (N = 494 patients). Two research team members reviewed the medication start and stop dates for each buprenorphine order and classified as retained (≥6 months of orders) or not retained (<6 months of orders). Logistic regressions estimated the odds of retention on buprenorphine by 1) patient characteristics and 2) timing of patient's engagement in buprenorphine treatment (pre- or post-implementation of an integrated treatment model).

resultsOf the study sample, 53% had ≥6 months of buprenorphine orders. Almost two times higher odds of retention were found among patients with ≥1 psychiatric comorbidity (versus none) and among those with buprenorphine orders in the post- versus pre-period.

conclusionsAn integrated, interdisciplinary model of OUD treatment was associated with ≥6 months of buprenorphine orders among our study population. Continued research is needed in real-world primary care settings to understand the impact of OUD treatment models on patient outcomes. A more nuanced examination of the associations between psychiatric diagnoses and buprenorphine treatment retention is warranted.

Indexed as

BuprenorphineOpioid-Related DisordersAdultAnalgesics, OpioidComorbidityHumansOpiate Substitution TreatmentPrimary Health CareAnalgesics, OpioidBuprenorphineBuprenorphineMedication for opioid use disorderOpioid use disorderRetention

Identifiers

PMID34244013
PMCPMC8664960

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.